Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma

Annals of Oncology

Volumn 11, Issue 11, 2000, Pages 1471-1476

  Belpomme, D ^a   Gauthier, S ^a   Pujade Lauraine, E ^b   Facchini, T ^c   Goudier, M J ^d   Krakowski, I ^e   Netter Pinon, G ^f   Frenay, M ^g   Gousset, C ^a   Marie F N ^a   Benmiloud, M ^a   Sturtz, F ^a  

^a Hopital Boucicaut   (France)

^b HÔTEL DIEU   (France)

^c Polyclinique de Courlancy   (France)

^d Hôpital Bodélio   (France)

^e CENTRE ALEXIS VAUTRIN   (France)

^f HÔPITAL DU BOCAGE   (France)

^g CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

5 FU continuous infusion; Metastatic breast carcinoma; Multidrug resistance; Verapamil

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; FLUOROURACIL; VERAPAMIL; VINDESINE;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INFUSION; MAJOR CLINICAL STUDY; METASTASIS; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR; STATISTICAL ANALYSIS;

EID: 0033635917     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026556119020     Document Type: Article

References (44)

1. Malignant tumors of the breast
2. Chemotherapy resistance in breast cancer
3. Drug resistance: Genotype vs. phenotype. Thirty-second G.H.A. Clowes Memorial Award Lecture
4. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
5. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
6. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance
7. Clinical trials of P-glycoprotein reversal in solid tumours
8. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
9. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: Association with level of drug resistance and drug accumulation
10. MDR1 gene expression in solid tumours
11. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
12. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy
13. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene
14. P-glycoprotein expression in treated and untreated human breast cancer
15. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gpl70 expression and its possible functional significance
16. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
17. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers
18. Reversal of drug-resistance in multiple myeloma with verapamil
19. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors
20. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil
21. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration
22. Oral verapamil with chemotherapy for advanced non-small-cell lung cancer: A randomised study
23. Treatment of advanced and refractory breast cancer with doxorubicin, vincristine and continuous infusion of verapamil. A phase I-II clinical trial
24. Does verapamil help overcome multidrug resistance in tumor cell lines and cancer patients?
25. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients
26. Randomized phase II study of single-agent epirubicin ± verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society
27. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer
28. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil
29. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
30. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using LI210/VCR cells
31. A comparative randomizect trial of vinca alkaloids in patients with metastatic breast carcinoma
32. Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma
33. The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy
34. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial
35. Stereoselective first-pass metabolism of highly cleared drugs: Studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique
36. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension
37. A phase lII randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma
38. Phase I and II study of oral verapamil (VRP) and intravenous vindesine (VDN)
39. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific
40. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts
41. Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells
42. Dexverapamil as an inhibitor of angiogenesis
43. Verapamil enhances antitumor activity without increasing myeloid toxicity
44. Apoptosis of human primary and metastatic colon adenocarcinoma cell lines in vitro induced by 5-fluorouracil, verapamil, and hyperthermia